{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:47:07Z","timestamp":1649047627552},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"19-20","license":[{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10354-015-0379-0","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T10:47:28Z","timestamp":1440413248000},"page":"410-418","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice"],"prefix":"10.1007","volume":"165","author":[{"given":"Margit","family":"Hemetsberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Pronai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"issue":"3","key":"379_CR1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/089686080002000308","volume":"20","author":"V Billa","year":"2000","unstructured":"Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int. 2000;20(3):315\u201321.","journal-title":"Perit Dial Int"},{"issue":"6","key":"379_CR2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0272-6386(97)90459-5","volume":"29","author":"MM Salem","year":"1997","unstructured":"Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997;29(6):862\u20135.","journal-title":"Am J Kidney Dis"},{"key":"379_CR3","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14\u20139.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"379_CR4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00041552-199607000-00008","volume":"5","author":"Y Tominaga","year":"1996","unstructured":"Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996;5(4):336\u201341.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"379_CR5","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","volume":"22","author":"T Drueke","year":"2007","unstructured":"Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 2007;22(7):1828\u201339.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"379_CR6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208\u201318.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"379_CR7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2362.2007.01840.x","volume":"37","author":"B Kestenbaum","year":"2007","unstructured":"Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest. 2007;37(8):607\u201322.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"379_CR8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.ajkd.2003.12.005","volume":"43","author":"WG Goodman","year":"2004","unstructured":"Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43(3):572\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"379_CR9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353.","journal-title":"Kidney Int"},{"issue":"15","key":"379_CR10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med"},{"issue":"3","key":"379_CR11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"1\u20132","key":"379_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00508-010-1515-x","volume":"123","author":"E Zitt","year":"2011","unstructured":"Zitt E, Jager C, Rosenkranz AR, Eigner M, Kodras K, Kovarik J, et al. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients\u2013results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr. 2011;123(1\u20132):45\u201352.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"379_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"379_CR14","unstructured":"Moe SM, Smirnakis KV, Ling X, Turner SA, Bushinsky DA, editors Early initiation of cinacalcet HCl for the treatment of secondary hyperparathyroidism (SHPT) improves KDOQITM goal attainment. Annual Meeting of the American Society of Nephrology; 2006; San Diego."},{"issue":"3","key":"379_CR15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfn654","volume":"24","author":"M Meola","year":"2009","unstructured":"Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009;24(3):982\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"379_CR16","first-page":"690-1","volume":"24","author":"H Terawaki","year":"2009","unstructured":"Terawaki H, Nakano H, Takeguchi F, Hasegawa T, Nakayama M, Okazaki M, et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant. 2009;24(2):690-1. (author reply 1\u20132).","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"379_CR17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfn717","volume":"24","author":"H Komaba","year":"2009","unstructured":"Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics\u2013fact or illusion? Nephrol Dial Transplant. 2009;24(3):707\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"379_CR18","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","volume":"5","author":"H Komaba","year":"2010","unstructured":"Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5(12):2305\u201314.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"379_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","volume":"53","author":"M Chonchol","year":"2009","unstructured":"Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197\u2013207.","journal-title":"Am J Kidney Dis"},{"issue":"4 Suppl\u00a03","key":"379_CR20","first-page":"1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl\u00a03):1\u2013201.","journal-title":"Am J Kidney Dis"},{"key":"379_CR21","unstructured":"KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1\u2013130."},{"key":"379_CR22","doi-asserted-by":"crossref","unstructured":"Block GA. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney international. 2003;64(87):S131\u20136.","DOI":"10.1046\/j.1523-1755.64.s87.20.x"},{"key":"379_CR23","unstructured":"Kramar R. \u00d6sterreichisches Dialyse- und Transplantationsregister, \u00d6DTR, Jahresbericht. 2012 der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie 2013. http:\/\/www.nephro.at\/oedr2012\/oedr2012.htm . Accessed 30 April 2014."}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-015-0379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-015-0379-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-015-0379-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T13:39:06Z","timestamp":1599485946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-015-0379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":23,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1007\/s10354-015-0379-0","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,25]]}}}